Big Promise For TransEnterix Robotic-Surgery Device, But Probably Won't Undermine Intuitive's Market

16 Oct 2017

FDA's recent clearance of TransEnterix's Senhance System signals broad potential for robotically-assisted surgeries but the device is more likely to grow its own space than compete directly with Intuitive Surgical's daVinci products in many cases, analysts suggest.

US FDA's 510(k) clearance of TransEnterix Inc.'s Senhance System could pave the way for big changes in laparoscopic surgery by increasing the number of such surgeries done with robotically-assisted surgical devices (RASD). But the new system is unlikely to pose a direct threat to Intuitive Surgical Inc.'s daVinci product line, analysts suggest.

FDA cleared the Senhance System Oct. 13 for minimally invasive surgeries including gynecological and colorectal procedures.